Semg.Ta
SEMG.TA operates in the drug retailing industry, generating revenue primarily through the sale of pharmaceuticals and related health products.
Business. SEMG.TA operates in the drug retailing industry, generating revenue primarily through the sale of pharmaceuticals and related health products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SEMG.TA operates in the drug retailing industry, generating revenue primarily through the sale of pharmaceuticals and related health products.
SEMG.TA maintains a relatively strong liquidity position, with a current ratio of 3.49, indicating the company can cover its short-term liabilities more than three times over with its current assets. However, the company's free cash flow is negative at -679,000, and capital expenditures are -1,101,000, suggesting ongoing investment in operations. The company's liquidity is rated as medium, with a key flag indicating that net cash is negative after subtracting total debt.
Profitability metrics for SEMG.TA are modest, with a return on equity of 1.71% and a return on assets of 1.1%. These figures are below the typical thresholds for high-performing drug retailers, indicating that the company is not generating strong returns relative to its equity or asset base.
The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests that SEMG.TA may have a relatively undiversified revenue stream. This could pose a risk if the company is overly reliant on a single market or product line.
Looking ahead, the company's growth trajectory is not clearly defined in the available data. There are no specific numeric deltas provided for the current or next fiscal year, and historical revenue growth is not detailed. This lack of forward-looking guidance makes it difficult to assess the company's potential for expansion or contraction.
Risk factors for SEMG.TA include a medium liquidity risk, as the company has a negative net cash position after accounting for total debt. The dilution risk is rated as low, with no immediate pressure from share issuance or other dilutive events. However, the company's capital structure includes long-term debt of 16,841,000, which could become a concern if interest rates rise or if the company's cash flow deteriorates.
Recent events for SEMG.TA are not detailed in the available data. There are no specific filings or transcripts provided that would indicate recent strategic moves, earnings surprises, or other material developments. This lack of recent activity suggests a relatively stable but uneventful period for the company.
- SEMG.TA has a strong current ratio but negative free cash flow, indicating potential liquidity challenges.
- The company's return on equity and return on assets are below industry benchmarks, suggesting suboptimal profitability.
- Revenue concentration and geographic exposure are not disclosed, raising concerns about diversification.
- Growth trajectory is unclear due to the absence of forward-looking guidance and historical revenue data.
- Liquidity risk is moderate, with a negative net cash position after debt, but dilution risk is low.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- SEMG.TA Market data — financials · 2026-05-29